Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) In ...
The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...
Simultaneous or rapid initiation of evidence-based therapies significantly improves quality of life and outcomes in patients with heart failure with moderately reduced or preserved ejection fraction, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback